Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)

NCT00768274 is registered in ClinicalTrials.gov with Resverlogix Corp as lead sponsor.

NCT NCT00768274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00768274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)
Lead sponsor
Resverlogix Corp
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2008
Completion date
August 31, 2009
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, atherosclerosis, cardiovascular disease, dyslipidemia